99 related articles for article (PubMed ID: 15706644)
1. Anti-interleukin-12 antibody for active Crohn's disease.
Kolls JK; Zhang Z
N Engl J Med; 2005 Feb; 352(6):627-8; author reply 627-8. PubMed ID: 15706644
[No Abstract] [Full Text] [Related]
2. Anti-interleukin-12 antibody for active Crohn's disease.
Orenstein R
N Engl J Med; 2005 Feb; 352(6):627-8; author reply 627-8. PubMed ID: 15703432
[No Abstract] [Full Text] [Related]
3. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
Fuss IJ; Becker C; Yang Z; Groden C; Hornung RL; Heller F; Neurath MF; Strober W; Mannon PJ
Inflamm Bowel Dis; 2006 Jan; 12(1):9-15. PubMed ID: 16374252
[TBL] [Abstract][Full Text] [Related]
4. High risk of infectious disease caused by salmonellae and mycobacteria infections in patients with Crohn disease treated with anti-interleukin-12 antibody.
Fieschi C; Allez M; Casanova JL
Clin Infect Dis; 2005 May; 40(9):1381. PubMed ID: 15825051
[No Abstract] [Full Text] [Related]
5. Cytokine-based therapies for Crohn's disease--new paradigms.
Cominelli F
N Engl J Med; 2004 Nov; 351(20):2045-8. PubMed ID: 15537904
[No Abstract] [Full Text] [Related]
6. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-12 antibody treatment for Crohn disease: potential risk of invasive disease due to mycobacteria and salmonellae infection.
MacLennan C; Lammas DA; Kumararatne DS
Clin Infect Dis; 2005 May; 40(9):1381-2. PubMed ID: 15825052
[No Abstract] [Full Text] [Related]
8. Autoimmunity: A case of mistaken identity.
Watford WT; O'Shea JJ
Nature; 2003 Feb; 421(6924):706-8. PubMed ID: 12610607
[No Abstract] [Full Text] [Related]
9. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy.
Bowman EP; Chackerian AA; Cua DJ
Curr Opin Infect Dis; 2006 Jun; 19(3):245-52. PubMed ID: 16645485
[TBL] [Abstract][Full Text] [Related]
10. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12/23 monoclonal antibody for psoriasis.
Okamoto H; Momohara S
N Engl J Med; 2007 May; 356(19):2003; author reply 2003. PubMed ID: 17494940
[No Abstract] [Full Text] [Related]
15. Astrocytes as antigen-presenting cells: expression of IL-12/IL-23.
Constantinescu CS; Tani M; Ransohoff RM; Wysocka M; Hilliard B; Fujioka T; Murphy S; Tighe PJ; Das Sarma J; Trinchieri G; Rostami A
J Neurochem; 2005 Oct; 95(2):331-40. PubMed ID: 16086689
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy.
Nakase H; Matsuura M; Uza N; Chiba T
Aliment Pharmacol Ther; 2011 Apr; 33(8):979-80; author reply 980-1. PubMed ID: 21434949
[No Abstract] [Full Text] [Related]
17. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17.
Rice L; Orlow D; Ceonzo K; Stahl GL; Tzianabos AO; Wada H; Aird WC; Buras JA
J Infect Dis; 2005 Apr; 191(8):1368-76. PubMed ID: 15776385
[TBL] [Abstract][Full Text] [Related]
20. [Clinical images in gastroenterology. Crohn's disease treated with Remicade].
Villanueva-Sáenz E; Wiener Carrillo I; Bolaños-Badillo LE; Blanco-Lucio RM
Rev Gastroenterol Mex; 2007; 72(4):381. PubMed ID: 18595330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
